In this Healio video, Alissa J. Cooper, MD, a thoracic oncologist at Dana-Farber Cancer Institute, discusses the TOP trial of osimertinib plus chemotherapy in high-risk patients with non-small cell ...
When I first stood in front of the mirror after my double mastectomy, I felt something completely unexpected. I was prepared ...
Most patients initiated full-dose ibrutinib, while reduced starting doses clustered in older, more comorbid, poorer ECOG ...
Stocktwits on MSN
SLS stock rises premarket ahead of cancer summit this month – investors eye phase 3 AML trial milestone
Sellas will present new data on its CDK9 inhibitor SLS009 at the American Association for Cancer Research (AACR) meeting on April 21. ・Preclinical findings showed SLS009 triggered leukemia cell death ...
Although ASCT improved PFS in all patients compared to CAR-T therapy, no differences in overall survival were noted between groups.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results